Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus HEMSOL HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus HEMSOL HC.
ALA-SCALP vs HEMSOL-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
Topical application of a 5% solution to the scalp twice daily.
Intravenous: 100 mg hydralazine hydrochloride (equivalent to 80.5 mg hydralazine base) administered over 30 minutes, every 6 hours as needed, for a maximum of 48 hours. Oral: 10–50 mg every 6 hours, adjusted based on response.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life: 1.2-2.5 hours; clinically, dose adjustments needed in hepatic impairment due to prolonged clearance
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal: >90% as unconjugated and conjugated metabolites; biliary/fecal: <10%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid